Merlin Nexus, based in New York, is a company focused on crossover private equity investing in the life sciences industry.
Merlin Nexus invests globally in private and public healthcare companies, and is among the most successful healthcare investment companies in the US. With its first fund launched in 2001 by Dominique Sémon, Merlin Nexus now has several crossover private equity funds and a public-only fund, with commitments totaling over $175 million.
Currently, the Merlin Nexus team consists of 5 investment professionals. Their varied healthcare backgrounds provide our firm with broad industry knowledge spanning later-stage biotechnology, specialty pharmaceuticals and medical devices.
We have a later-stage investment focus as compared to traditional venture capital firms, and we invest opportunistically and selectively. This approach has resulted in a significant number of profitable exits from investments, and consistently high returns which are benchmarked.
Our investor base consists of financial institutions, funds of funds, family offices and high net worth individuals.